American Brachytherapy Task Group Report

A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer

Jyoti Mayadev, Akila Viswanathan, Yu Liu, Chin Shang Li, Kevin Albuquerque, Antonio L. Damato, Sushil Beriwal, Beth Erickson

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Purpose Advanced imaging used in combination with brachytherapy (BT) has revolutionized the treatment of patients with cervical cancer. We present a comprehensive review of the literature for definitive radiation with high-dose-rate (HDR) BT. In addition, we investigate potential outcome improvement with image-based brachytherapy (IBBT) compared to studies using traditional Point A dosing. This review extensively investigates acute and late toxicities. Methods and Materials This study reviews the literature from 2000 to 2015 with an emphasis on modern approaches including concurrent chemotherapy (chemoRT), radiation, and HDR BT and IBBT. Descriptive statistics and pelvic control (PC), disease-free survival (DFS), and overall survival (OS) outcomes were calculated using weighted means to report pooled analysis of outcomes. Results Literature search yielded 16 prospective, 51 retrospective studies that reported survival outcomes, and 13 retrospective studies that focused on acute and late toxicity outcomes regardless of applicator type. There are 57 studies that report Point A dose specification with 33 having chemoRT, and 10 studies that use IBBT, 8 with chemoRT. Patients receiving radiation and chemoRT with HDR BT in the prospective studies, with >24 months followup, rates of PC were: for RT: 73%, SD: 11; CRT: 82%, SD: 8; DFS—RT: 55%, SD: 10; CRT: 65%, SD: 7; OS—RT: 66%, SD: 7; CRT: 70%, SD: 11. In the retrospective studies, the PC rates (weighted means) for the radiation and chemoradiation outcomes are 75% vs. 80%, and for DFS, the values were 55% vs. 63%, respectively. Comparing patients receiving chemoRT and IBBT to traditional Point A dose specification, there is a significant improvement in PC (p < 0.01) and DFS (p < 0.01) with IBBT. The range of genitourinary late toxicity reported for radiation was Grade 3: 1–6% and for chemoRT 2–20%. The range of late gastrointestinal toxicity for radiation was Grade 3: 4–11% and for chemoRT, 1–11%. For the late gynecologic toxicity, only 1 of the 16 prospective trials report a Grade 1–2 of 17% for radiation and 9% for chemoRT effects. Conclusions We present concise outcomes of PC, DFS, OS, and toxicity for cervical cancer patients treated with chemoradiation and HDR BT. Our data suggest an improvement in outcomes with the use of IBBT compared with traditional Point A dose prescriptions. In conclusion, HDR BT is a safe, effective modality when combined with IBBT.

Original languageEnglish (US)
Pages (from-to)22-43
Number of pages22
JournalBrachytherapy
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Brachytherapy
Uterine Cervical Neoplasms
Radiation
Disease-Free Survival
Retrospective Studies
Survival
Prescriptions

Keywords

  • Brachytherapy
  • Cervical cancer
  • HDR
  • Image guidance
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

American Brachytherapy Task Group Report : A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer. / Mayadev, Jyoti; Viswanathan, Akila; Liu, Yu; Li, Chin Shang; Albuquerque, Kevin; Damato, Antonio L.; Beriwal, Sushil; Erickson, Beth.

In: Brachytherapy, Vol. 16, No. 1, 01.01.2017, p. 22-43.

Research output: Contribution to journalReview article

Mayadev, Jyoti ; Viswanathan, Akila ; Liu, Yu ; Li, Chin Shang ; Albuquerque, Kevin ; Damato, Antonio L. ; Beriwal, Sushil ; Erickson, Beth. / American Brachytherapy Task Group Report : A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer. In: Brachytherapy. 2017 ; Vol. 16, No. 1. pp. 22-43.
@article{9c8507f9ae0d4e2c8619000b9153749c,
title = "American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer",
abstract = "Purpose Advanced imaging used in combination with brachytherapy (BT) has revolutionized the treatment of patients with cervical cancer. We present a comprehensive review of the literature for definitive radiation with high-dose-rate (HDR) BT. In addition, we investigate potential outcome improvement with image-based brachytherapy (IBBT) compared to studies using traditional Point A dosing. This review extensively investigates acute and late toxicities. Methods and Materials This study reviews the literature from 2000 to 2015 with an emphasis on modern approaches including concurrent chemotherapy (chemoRT), radiation, and HDR BT and IBBT. Descriptive statistics and pelvic control (PC), disease-free survival (DFS), and overall survival (OS) outcomes were calculated using weighted means to report pooled analysis of outcomes. Results Literature search yielded 16 prospective, 51 retrospective studies that reported survival outcomes, and 13 retrospective studies that focused on acute and late toxicity outcomes regardless of applicator type. There are 57 studies that report Point A dose specification with 33 having chemoRT, and 10 studies that use IBBT, 8 with chemoRT. Patients receiving radiation and chemoRT with HDR BT in the prospective studies, with >24 months followup, rates of PC were: for RT: 73{\%}, SD: 11; CRT: 82{\%}, SD: 8; DFS—RT: 55{\%}, SD: 10; CRT: 65{\%}, SD: 7; OS—RT: 66{\%}, SD: 7; CRT: 70{\%}, SD: 11. In the retrospective studies, the PC rates (weighted means) for the radiation and chemoradiation outcomes are 75{\%} vs. 80{\%}, and for DFS, the values were 55{\%} vs. 63{\%}, respectively. Comparing patients receiving chemoRT and IBBT to traditional Point A dose specification, there is a significant improvement in PC (p < 0.01) and DFS (p < 0.01) with IBBT. The range of genitourinary late toxicity reported for radiation was Grade 3: 1–6{\%} and for chemoRT 2–20{\%}. The range of late gastrointestinal toxicity for radiation was Grade 3: 4–11{\%} and for chemoRT, 1–11{\%}. For the late gynecologic toxicity, only 1 of the 16 prospective trials report a Grade 1–2 of 17{\%} for radiation and 9{\%} for chemoRT effects. Conclusions We present concise outcomes of PC, DFS, OS, and toxicity for cervical cancer patients treated with chemoradiation and HDR BT. Our data suggest an improvement in outcomes with the use of IBBT compared with traditional Point A dose prescriptions. In conclusion, HDR BT is a safe, effective modality when combined with IBBT.",
keywords = "Brachytherapy, Cervical cancer, HDR, Image guidance, Radiation",
author = "Jyoti Mayadev and Akila Viswanathan and Yu Liu and Li, {Chin Shang} and Kevin Albuquerque and Damato, {Antonio L.} and Sushil Beriwal and Beth Erickson",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.brachy.2016.03.008",
language = "English (US)",
volume = "16",
pages = "22--43",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - American Brachytherapy Task Group Report

T2 - A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer

AU - Mayadev, Jyoti

AU - Viswanathan, Akila

AU - Liu, Yu

AU - Li, Chin Shang

AU - Albuquerque, Kevin

AU - Damato, Antonio L.

AU - Beriwal, Sushil

AU - Erickson, Beth

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose Advanced imaging used in combination with brachytherapy (BT) has revolutionized the treatment of patients with cervical cancer. We present a comprehensive review of the literature for definitive radiation with high-dose-rate (HDR) BT. In addition, we investigate potential outcome improvement with image-based brachytherapy (IBBT) compared to studies using traditional Point A dosing. This review extensively investigates acute and late toxicities. Methods and Materials This study reviews the literature from 2000 to 2015 with an emphasis on modern approaches including concurrent chemotherapy (chemoRT), radiation, and HDR BT and IBBT. Descriptive statistics and pelvic control (PC), disease-free survival (DFS), and overall survival (OS) outcomes were calculated using weighted means to report pooled analysis of outcomes. Results Literature search yielded 16 prospective, 51 retrospective studies that reported survival outcomes, and 13 retrospective studies that focused on acute and late toxicity outcomes regardless of applicator type. There are 57 studies that report Point A dose specification with 33 having chemoRT, and 10 studies that use IBBT, 8 with chemoRT. Patients receiving radiation and chemoRT with HDR BT in the prospective studies, with >24 months followup, rates of PC were: for RT: 73%, SD: 11; CRT: 82%, SD: 8; DFS—RT: 55%, SD: 10; CRT: 65%, SD: 7; OS—RT: 66%, SD: 7; CRT: 70%, SD: 11. In the retrospective studies, the PC rates (weighted means) for the radiation and chemoradiation outcomes are 75% vs. 80%, and for DFS, the values were 55% vs. 63%, respectively. Comparing patients receiving chemoRT and IBBT to traditional Point A dose specification, there is a significant improvement in PC (p < 0.01) and DFS (p < 0.01) with IBBT. The range of genitourinary late toxicity reported for radiation was Grade 3: 1–6% and for chemoRT 2–20%. The range of late gastrointestinal toxicity for radiation was Grade 3: 4–11% and for chemoRT, 1–11%. For the late gynecologic toxicity, only 1 of the 16 prospective trials report a Grade 1–2 of 17% for radiation and 9% for chemoRT effects. Conclusions We present concise outcomes of PC, DFS, OS, and toxicity for cervical cancer patients treated with chemoradiation and HDR BT. Our data suggest an improvement in outcomes with the use of IBBT compared with traditional Point A dose prescriptions. In conclusion, HDR BT is a safe, effective modality when combined with IBBT.

AB - Purpose Advanced imaging used in combination with brachytherapy (BT) has revolutionized the treatment of patients with cervical cancer. We present a comprehensive review of the literature for definitive radiation with high-dose-rate (HDR) BT. In addition, we investigate potential outcome improvement with image-based brachytherapy (IBBT) compared to studies using traditional Point A dosing. This review extensively investigates acute and late toxicities. Methods and Materials This study reviews the literature from 2000 to 2015 with an emphasis on modern approaches including concurrent chemotherapy (chemoRT), radiation, and HDR BT and IBBT. Descriptive statistics and pelvic control (PC), disease-free survival (DFS), and overall survival (OS) outcomes were calculated using weighted means to report pooled analysis of outcomes. Results Literature search yielded 16 prospective, 51 retrospective studies that reported survival outcomes, and 13 retrospective studies that focused on acute and late toxicity outcomes regardless of applicator type. There are 57 studies that report Point A dose specification with 33 having chemoRT, and 10 studies that use IBBT, 8 with chemoRT. Patients receiving radiation and chemoRT with HDR BT in the prospective studies, with >24 months followup, rates of PC were: for RT: 73%, SD: 11; CRT: 82%, SD: 8; DFS—RT: 55%, SD: 10; CRT: 65%, SD: 7; OS—RT: 66%, SD: 7; CRT: 70%, SD: 11. In the retrospective studies, the PC rates (weighted means) for the radiation and chemoradiation outcomes are 75% vs. 80%, and for DFS, the values were 55% vs. 63%, respectively. Comparing patients receiving chemoRT and IBBT to traditional Point A dose specification, there is a significant improvement in PC (p < 0.01) and DFS (p < 0.01) with IBBT. The range of genitourinary late toxicity reported for radiation was Grade 3: 1–6% and for chemoRT 2–20%. The range of late gastrointestinal toxicity for radiation was Grade 3: 4–11% and for chemoRT, 1–11%. For the late gynecologic toxicity, only 1 of the 16 prospective trials report a Grade 1–2 of 17% for radiation and 9% for chemoRT effects. Conclusions We present concise outcomes of PC, DFS, OS, and toxicity for cervical cancer patients treated with chemoradiation and HDR BT. Our data suggest an improvement in outcomes with the use of IBBT compared with traditional Point A dose prescriptions. In conclusion, HDR BT is a safe, effective modality when combined with IBBT.

KW - Brachytherapy

KW - Cervical cancer

KW - HDR

KW - Image guidance

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=85009876411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009876411&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2016.03.008

DO - 10.1016/j.brachy.2016.03.008

M3 - Review article

VL - 16

SP - 22

EP - 43

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

IS - 1

ER -